RxDoctor Payments Data

Kenneth Levy, MD

Internal Medicine · Phoenix, AZNPI 1174712806

Payments from drug & device makers

$13,556in general payments, 2019–2025

Across 719 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$934
  • Boehringer Ingelheim$922
  • GSK$918
  • Lilly USA, LLC$863
  • Novo Nordisk$709
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$13,535100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)88$1,759
AstraZeneca34$934
Boehringer Ingelheim37$922
GSK92$918
Lilly USA, LLC52$863
Novo Nordisk30$709
Pfizer51$695
Sanofi-aventis U.S. LLC38$570
Johnson & Johnson29$566
Amgen(2 entities)32$529
Otsuka America Pharmaceutical, Inc.14$435
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$390
Astellas Pharma US Inc13$359
Sumitomo Pharma America, Inc.16$347
Eisai Inc.13$336
Abbott15$284
Novartis16$262
Kowa Pharmaceuticals America, Inc.13$207
Bayer8$195
Nestle Healthcare Nutrition Inc.10$187
Amarin Pharma, Inc.11$170
Merck10$147
Axsome Therapeutics, Inc.1$122
Mannkind Corporation6$112
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$102
Alkermes, Inc.1$94
Avanir Pharmaceuticals, Inc.6$88
Sunovion Pharmaceuticals Inc.6$83
Aimmune Therapeutics, Inc.4$78
Medtronic(3 entities)5$77
Esperion Therapeutics, Inc.4$76
Acadia Pharmaceuticals Inc3$71
Brainsway USA Inc1$69
Idorsia Pharmaceuticals US Inc4$56
Shire North American Group Inc3$52
E.r. Squibb & Sons, L.L.C.3$51
Ultragenyx Pharmaceutical Inc.3$50
Bardy Diagnostics, Inc.3$45
Nevro Corp.2$43
Lifescan, Inc.2$42
Mylan Specialty L.p.2$39
Biohaven Pharmaceuticals, Inc.2$30
Corcept Therapeutics2$29
Xeris Pharmaceuticals, Inc.1$27
Cequr Corporation1$27
Edwards Lifesciences1$26
Dexcom, Inc.1$23
Inspire Medical Systems, Inc.1$21
Corium, LLC1$19
Noven Therapeutics, LLC1$19
Hikma Pharmaceuticals USA1$18
Insulet Corporation1$17
Boston Scientific1$16
Biogen1$16
Radius Health, Inc.1$15
Qiagen, LLC1$15
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$14
Lundbeck LLC1$14
Optos, Inc.1$13
Aytu Biopharma, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,556 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$133,065
Medicare patients
250
Services billed
1,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$174,741
OzempicSemaglutide126$165,290
MounjaroTirzepatide112$147,734
ZenpepLipase/Protease/Amylase13$77,381
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$58,982
MyrbetriqMirabegron57$53,737
FarxigaDapagliflozin Propanediol39$53,464
JanuviaSitagliptin Phosphate39$53,117
LinzessLinaclotide59$44,124
XareltoRivaroxaban28$34,266
GemtesaVibegron29$29,347
VraylarCariprazine Hcl15$19,723
NexlizetBempedoic Acid/Ezetimibe16$19,344
Tresiba Flextouch U-200Insulin Degludec14$18,431
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$17,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$695$174,741134 claims
Novo NordiskOzempic$709$165,290126 claims
Lilly USA, LLCMounjaro$863$147,734112 claims
Aimmune Therapeutics, Inc.Zenpep$78$77,38113 claims
AstraZenecaFarxiga, Breztri Aerosphere$934$69,28455 claims
AbbVieLinzess, Vraylar, Synthroid$1,759$67,327123 claims
GSKTrelegy Ellipta, Arnuity Ellipta$918$63,07877 claims
Astellas Pharma US IncMyrbetriq$359$53,73757 claims
MerckJanuvia$147$53,11739 claims
Johnson & JohnsonXarelto$566$34,26628 claims
Sumitomo Pharma America, Inc.Gemtesa$347$29,34729 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$922$26,14137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →